(Adnkronos) - ‘Già autorizzato in altre patologie autoimmuni upadacitinib è in sperimentazione clinica per il Lupus eritematoso sistemico’.
Category
🗞
NewsTranscript
00:00Improving the standards of care and clinical results for patients suffering from rheumatological diseases and not only.
00:11With these goals, AVI has focused attention on its inhibitor, Upadacitinib.
00:17This oral therapy, authorized for other autoimmune diseases, is already available in Italy
00:22and is also being studied for the treatment of a complex disease such as lupus erythematosus systemic.
00:27But where does the commitment of this pharmaceutical company for lupus erythematosus come from?
00:31We asked Caterina Golotta, Director of AVI Italy.
00:35AVI is an ultraventricular experience in rheumatology
00:38and brings in this therapeutic area the approach of improving the standards of care
00:44and improving the results for patients suffering from rheumatological diseases.
00:51Specifically, lupus erythematosus systemic, or LES, is an extremely complex autoimmune disease
00:58characterized by the production of autoantibodies
01:02that can hit various organs and systems in a varied and heterogeneous way.
01:08The pulmonary system, the skeletal muscle system, the cuticle and the central nervous system.
01:14Clearly, the symptoms vary depending on the type of narrow organ involved.
01:20Lupus erythematosus has an extremely unpredictable chronic course.
01:23That is why the unsatisfied need is very strong
01:28and AVI is committed to developing a possible further tool for doctors
01:35to respond to the needs of patients suffering from this pathology.
01:40Specifically, our inhibitor of JAK, lupatacitinib,
01:45is currently undergoing clinical experimentation in this context.
01:49And what is this therapy specifically about?
01:51On which pathologies has it shown to act positively?
01:54Lupatacitinib is our inhibitor of JAK
01:57and is the result of the effort, research and internal development of AVI.
02:00It is an irreversible selective inhibitor of JAK-Inasi
02:04and is currently approved and reimbursed in a series of immunological pathologies.
02:10Arthritis rheumatoide, spondylitis architosanthe,
02:13psoriasis arthritis, colitis ulcerosa and atopic dermatitis.
02:18We remain confident of the results of the molecule
02:22in the development program of lupus erythematosus.
02:26Among other things, lupatacitinib is currently being studied
02:30in two other pathologies of the immunological field,
02:33vitiligin and alopecia areata.
02:36But what does AVI do?
02:39AVI is a global biopharmaceutical company
02:42based on research, focused on patients
02:45and specifically on innovation and research and development,
02:48with the aim of having a significant impact on the lives of patients
02:53and focusing on therapeutic areas of which it has great experience.
02:57Immunology, oncology, virology, neurosciences,
03:01ophthalmology and aesthetic medicine.
03:04We are present in the world in more than 70 countries
03:07with about 47,000 employees.
03:10In general, AVI's research commitment in 2024
03:13was equal to about 13 billion dollars,
03:16which represents an increase of 66.66%
03:20compared to the commitment of 2023.
03:23In our country, this company is carrying out
03:2678 clinical studies involving about 400 experimental centers.
03:30In Italy, the history of AVI is long.
03:33We have been present since 1949 with Abbott.
03:36AVI was born in 2013 as a spin-off of Abbott
03:41and today has about 1,700 employees in Italy.
03:45Half of these employees work in the Campoverde production pole,
03:49which represents a flagship for us.
03:52The company has invested a lot in the Campoverde pole
03:56to bring it to very high standards of competitiveness
03:59and environmental sustainability.
04:02These standards have allowed us to bring to our country
04:05the production of many active-principle drugs
04:08that make them available in the world.